Lanfranco Pellesi
Overview
Explore the profile of Lanfranco Pellesi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pellesi L, Edvinsson L
J Headache Pain
. 2025 Jan;
26(1):22.
PMID: 39891050
Substance P, previously dismissed as a therapeutic target for migraine due to the failure of neurokinin-1 receptor antagonists, warrants renewed attention. Building on the success of therapies targeting the calcitonin...
2.
Petrusic I, Chiang C, Garcia-Azorin D, Ha W, Ornello R, Pellesi L, et al.
J Headache Pain
. 2025 Jan;
26(1):2.
PMID: 39748331
Part 2 explores the transformative potential of artificial intelligence (AI) in addressing the complexities of headache disorders through innovative approaches, including digital twin models, wearable healthcare technologies and biosensors, and...
3.
Pellesi L, Garcia-Azorin D, Rubio-Beltran E, Ha W, Messina R, Ornello R, et al.
J Headache Pain
. 2024 Dec;
25(1):214.
PMID: 39639191
Combination treatments for migraine prophylaxis present a promising approach to addressing the diverse and complex mechanisms underlying migraine. This review explores the potential of combining oral conventional prophylactics, onabotulinumtoxin A,...
4.
Raggi A, Leonardi M, Arruda M, Caponnetto V, Castaldo M, Coppola G, et al.
J Headache Pain
. 2024 Nov;
25(1):189.
PMID: 39482575
Background And Aim: Migraine is a common disabling conditions which, globally, affects 15.2% of the population. It is the second cause of health loss in terms of years lived with...
5.
Pellesi L, Onan D, Martelletti P
Toxins (Basel)
. 2024 Oct;
16(10).
PMID: 39453203
Post-traumatic headache (PTH) is a common and debilitating consequence of traumatic brain injury (TBI), often resembling migraine and tension-type headaches. Despite its prevalence, the optimal treatment for PTH remains unclear,...
6.
Wells-Gatnik W, Pellesi L, Martelletti P
Expert Rev Neurother
. 2024 Sep;
24(11):1107-1117.
PMID: 39264231
Introduction: Rimegepant and atogepant, two innovative oral medications for the treatment of migraine, are gaining prominence in the treatment of migraine. However, outside of specialist headache centers, these novel medications...
7.
Pellesi L, Martelletti P
J Headache Pain
. 2024 Aug;
25(1):137.
PMID: 39174943
This commentary addresses the use of rimegepant for situational prevention in migraine management. While the approach of using prophylactic treatments during high-risk periods is not new, its application with rimegepant...
8.
Halloum W, Dughem Y, Beier D, Pellesi L
J Headache Pain
. 2024 Jul;
25(1):112.
PMID: 38997662
Background: Glucagon-like peptide-1 (GLP-1) plays a crucial role in metabolic disorders by enhancing insulin secretion, inhibiting glucagon release, and slowing gastric emptying, thereby improving glycemic control. In recent years, GLP-1...
9.
Baraldi C, Beier D, Martelletti P, Pellesi L
Expert Opin Drug Discov
. 2024 Jun;
19(7):783-788.
PMID: 38856039
Introduction: Atogepant is a selective calcitonin gene-related peptide (CGRP) receptor antagonist that is utilized in adults for the prevention of episodic and chronic migraine. Cumulative findings support the involvement of...
10.
Pellesi L, Do T, Hougaard A
Expert Opin Pharmacother
. 2024 May;
25(6):673-683.
PMID: 38720629
Introduction: Migraine is a complex neurological disorder that affects a significant portion of the global population. As traditional pharmacological approaches often fall short in alleviating symptoms, the development of innovative...